News blog

Flu focus pays off for GSK

GlaxoSmithKline has announced a rosy set of third-quarter financial figures, and is going to be boosted by the ongoing H1N1 outbreak.

The company says it expects further growth in the fourth quarter “including significant sales of influenza products”.

BACK TO ARTICLE

Your details are incomplete or incorrect, please amend the following information

%s

Tell a Friend

Your friend's email address (Required)

Your email (Required)

Message subject (Required)

Message

Verify (Required)

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE